Celgene: Is It a Buy?

Celgene (NASDAQ:CELG), among other biotech companies, has fallen from its record high. The company has returned negative 15% for the past year, and negative 26% from its high of $134 a share back in July 2015 compared to its Tuesday morning price of $96.89 a share. The iShares NASDAQ Biotechnology Index ETF, on the other hand, has performed worst at negative 32% for the past year. Along with leveraged commodity ETFs, the biotech sector has experienced Mr. Market’s dark side. The Standard & Poor’s 500 returned -2% in the same timeframe.

read more here http://www.gurufocus.com/news/422774/celgene-is-it-a-buy

“If you can’t beat the market, be the market.” Seth Klarman (Trades, Portfolio)